anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
We report a case of numb chin syndrome caused by a small cortical infarction in the postcentral gyrus. A 67-year-old man suddenly developed numbness in his right lower lip and the chin. There were no apparent abnormal neurological symptoms other than numbness. MRI revealed a fresh small infarction in the left postcentral gyrus, which corresponds with the somatosensory area of the lower lip and the chin drawn by Penfield and Rasmussen. MRA showed no significant stenosis in the main trunk of the cerebral arteries. A soft plaque with irregular wall was detected in the left carotid bifurcation on carotid ultrasonography. Based on these findings, we diagnosed him with arteriogenic cerebral embolism, and started antiplatelet therapy. A small infarction in the postcentral gyrus can cause numbness in the lower lip and the chin, which can be considered numb chin syndrome. Numb chin syndrome due to thalamic infarction has been reported previously. The present case is the first numb chin syndrome caused by a small cortical infarction in the postcentral gyrus.
Increased blood pressure. In the postpartum hemorrhage series, 5/115 (4%) of patients had an increase of blood pressure reported as a side effect. The degree of hypertension was moderate and it is not certain as to whether this was in fact due to a direct effect of HEMABATE or a return to a status of pregnancy associated hypertension manifest by the correction of hypovolemic shock. In any event the cases reported did not require specific therapy for the elevated blood pressure.

Use in patients with chorioamnionitis. During the clinical trials with HEMABATE, chorioamnionitis was identified as a complication contributing to postpartum uterine atony and hemorrhage in 8/115 (7%) of cases, 3 of which failed to respond to HEMABATE. This complication during labor may have an inhibitory effect on the uterine response to HEMABATE similar to what has been reported for other oxytocic agents.1

* * *

1
    Duff, Sanders, and Gibbs; The course of labor in term patients with chorioamnionitis; Am. J. Obstet. Gynecol.; vol. 147, no. 4, October 15, 1983 pp 391–395.
Subjects received three doses of the control Menjugate™ vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, on a 0, 1, 7 months schedule. The first two doses were administered 1 month apart during the primary vaccination phase and the third dose was administered 6 months after the last primary vaccination dose.
The invention discloses a black tea double yeast fermentation product, a cosmetic and a preparation method and application thereof, and relates to the technical field of cosmetics. The preparation method comprises the following steps: black tea is used as a fermentation base material, double yeasts are used as fermentation strains, and the black tea is prepared through liquid aerobic fermentation; the double yeasts are respectively deposited with the accession numbers of GDMCC:62570, and a progeny yeast thereof, and having a accession number GDMCC:62571 or progeny yeasts thereof. The cosmetic raw material prepared by the preparation method has extremely high safety and natural property, and no other chemicals are added except the basic culture medium component in the fermentation process. Really safe, natural and pure. The obtained black tea fermentation filtrate is subjected to efficacy test, and has good effects of antioxidation, anti-aging and brightening. The color of the raw material of the cosmetic prepared by the invention is reddish brown transparent liquid, which accords with the inherent characteristics of black tea.
Arbuscular mycorrhizal (AM) fungi play a crucial role in protecting host plants from pathogens. AM fungal taxa show varying abilities to hinder the development of plant pathogens with various underlying mechanisms of action, and plant defense through mycorrhization should be viewed to have a continuum of several possible mechanisms. However, an additive or synergistic effect is not always achieved. This review examines the potential mechanisms by which AM fungi enhance plant tolerance and defense against pathogens, as well as the possible interactive mechanisms among AM fungal traits that may lead to facilitative and antagonistic effect on plant defense outcomes. It also provides evidence demonstrating the benefits of AM fungal consortia used so far to protect crop plants from various pathogens. It concludes by proposing some biotechnological applications aimed at unraveling the connections between AM fungal diversity and their function to enhance efficacy of plant pathogen protection.
Apply silicone dressing after wound completely healed. Changing the dressing sheet every 7 days by Close the silicone cover for 10 weeks.
PURPOSE:To obtain the titled capsule efficiently, by using a solution containing a water-soluble drug and a substance to retain a drug as an inner water layer, raising the viscosity of it to a specific viscosity or solidifying it, preparing an emulsion by the use of a solution containing a high-molecular-weight polymer as an oily layer, subjecting it to drying method in water. CONSTITUTION:A W/O type emulsion comprising 0.001-90wt% water-soluble drug (having high hydrophilic nature and low partition coefficient of oil and water: polypeptide such as leuteinizing hormone-releasing hormone, etc, having physiological activity, antibiotic such as gentamicin, etc., antipyretic, analgesic, anti-inflammatory drug, etc. such as sodium salicylate, etc.), and a solution containing 0.05-80wt% substance to keep a drug (e.g., natural or synthetic rubber, high polymer compound) is prepared. In the operation, viscosity of the inner water layer is raised to >=about 500cp or it is solidified, the prepared emulsion is subjected to drying method in water, to give a sustained release microcapsule of the water-soluble drug. It has low aggregation of capsule each other, and uniform sphericity.
Hemorrhoids are commonly observed surgical conditions affecting the anorectal area, characterized by symptoms such as pain, bleeding, and the presence of a protruding mass from the anal opening. Fear of postoperative pain is one of the most important factors for patients to avoid surgical interventions. Postoperative pain is a significant concern, with over 80% of patients encountering moderate to severe pain. This heightened pain level contributes to an elevated risk of complications including atelectasis, thromboembolism, myocardial ischemia, cardiac arrhythmia, electrolyte imbalance, urinary retention, and ileus. The two main unresolved issues following surgery are postoperative pain and urinary retention. In addition to improving patient satisfaction, pain management will decrease urinary retention and constipation, especially in the first 24 hours following surgery. According to earlier research, even with analgesic therapy, 20% to 40% of patients who underwent hemorrhoidectomy would experience severe postoperative pain. Commonly used pain relievers like nonsteroidal anti-inflammatory drugs, paracetamol, and opioids often come with adverse effects such as dizziness, nausea, vomiting, and constipation and can even lead to tolerance. These side effects could prevent a full recovery and result in a poor prognosis. Bilateral pudendal nerve blocks are said to significantly reduce postoperative pain, but they are technically difficult and require specific positioning. Furthermore, the administration of pudendal nerve block carries the risk of potential complications, including hematoma formation, sciatic nerve injury, and accidental rectal puncture. Therefore, an alternative analgesic method with minimal adverse effects would be beneficial.

The erector spinae plane block (ESPB) was initially introduced as an interfascial plane block performed at the upper thoracic levels with the purpose of alleviating neuropathic pain. Subsequently, its application expanded to encompass a range of thoracic interventions, including mastectomy, video-assisted thoracoscopy (VATS), and cardiac surgery, while also being utilized at lumbar levels for procedures such as abdominal surgery, prostatectomy, lumbar spine surgery, total hip arthroplasty, and proximal femur surgery. A newly introduced method called the sacral Erector Spinae Plane Block (ESPB) has been recently documented in scientific literature. Case studies have demonstrated its effectiveness in various surgical procedures. Specifically, it has shown promise in managing radicular pain at the L5-S1 level after sex reassignment surgery and hypospadias surgery, as well as providing analgesia for the posterior branches of the sacral nerves during pilonidal sinus surgery.

The main hypothesis is that performing ESPB from the sacral level would result in effective analgesia following hemorrhoidectomy. It is also hypothesized that sacral ESPB would reduce the use of additional analgesics after hemorrhoidectomy and increase patient satisfaction. In this prospective, randomized, controlled trial, the main objective is to examine the postoperative analgesic effects of sacral ESPB following hemorrhoidectomy.
Participants assigned to the Exercise arm will receive a packet of materials from the study interventionist, along with a brief (10 minute) personalized introduction to the home-based exercise intervention. On Day 30 post hematopoietic cell transplantation (HCT), participants will meet briefly with the same interventionist when possible. To minimize contamination across intervention conditions, participants randomized to Exercise will be provided with only general advice regarding stress management (i.e., to continue using any techniques they currently use to manage stress). The interventionist will meet with the patient again in person or by phone at approximately 60 days post transplant.
The present probiotics, compising lactic acid bacteria and a component of plant origin, is characterized by improved survival, viability of microorganisms and very good multiplication, and have high antimicrobial activity against pathogenic microorganisms, such as E. coli, Listeria ssp., St . aureus, which leads to reducing of morbidity and mortality, and further have better adhesion to the intestinal surface and demonstrates high cell bioavailability. The composition has high protein content, the amount of free amino acids is increased, and the high content of oligosaccharides leads to easier digestion. Its application in animal husbandry leads to an increase in live weight of the animals while providing healthy nutrition and breeding, suppressing the putrefactive processes in the intestine and helping to restore and maintain beneficial gut microflora, having a beneficial effect on intestinal function through the production of lactic acid. The utility model for achieving the objective set forth is probiotics containing a protein plant-based product from sunflower flour, containing crude protein from 25.0 to 30.0 wt.%, Carbohydrates from 8.0 to 11.0%, fats 0.3-0 , 6%, fibers 8.0-15.0% and free amino acids from 39.0 to 40.0%, such as lysine, methionine, cystine, threonine, leucine, methylcystine, aspartic acid, serine, glutamic acid, glycine, alanine , valine, isoleucine, phenylalanine, histidine, arginine and a microbial component consisting of Lastobasillus acidophilus, No NBIMCC 8242; Lactobacillus delbrueckii subsp. bulgaricus, No NBIMCC 8250; Lastobasillus delbrueckii subsp. bulgaricus, No NBIMCC 8244; Lastobasillus delbrueckii subsp. lactis, No NBIMCC 8269; Streptococcus thermophilus, No NBIMCC 8253; Streptococcus faecium (Enterococcus faecium), No NBIMCC 8270 in an amount of not less than 10 9 cfu/g.
A transgene for producing recombinant polypeptides in the milk of transgenic bovine species comprises at least one expression regulation sequence, a secretory DNA sequence encoding a secretory signal sequence which is functional in mammary secretory cells of the bovine species and a recombinant DNA sequence encoding the recombinant polypeptide. Also included are methods for producing transgenic bovine species. The method includes introducing the above transgene into an embryonal target cell of a bovine species, transplanting the trangenic embryonic target cell formed thereby into a recipient bovine parent and indentifying at least one female offspring which is capable of producing the recombinant polypeptide in its milk. The invention also includes transgenic bovine species as well as the milk from such transgenic bovine species. Methods are also provided for producing transgenic non-human mammals having a desirable phenotype. The method comprises first methylating a transgene followed by introduction into fertilized oocytes. The oocytes are then cultured to form pre-implantation embryons. Thereafter, at least one cell is removed from each of the pre-implantation embryons and the DNA digested with a restriction endonuclease capable of cleaving the methylated transgene but incapable of cleaving the unmethylated form of the transgene.
A composition containing nanoparticles of gold and method for its production relate to the field of the chemical technology, namely to nanocompositions containing the metallic silver in nanodisperse state. The technical result consists in obtaining the stable composition combining the consumer properties and low toxicity, which provides for the highly effective composition for food and pharmaceutical industries. The essence of the invention consists in using at least one carbohydrate as the stabilizer. This may be monosaccharide, disaccharide or soluble polysaccharide. The natural carbohydrate complex, namely the honey, may be used as a stabilizer. The composition contains (in mass %) 0.000001-10% of nanoparticles and 1-90% of the carbohydrate with water or aqueous-alcohol complex representing the rest. The composition is produced by reaction of the solution of gold hydrochloric acid with the reducing agent in the presence of the stabilizer, namely the carbohydrate, and in the presence of hydroxide of alkaline or alkaline-earth metal and/or citrate and/or sodium ascorbate. The composition can be used for manufacturing food, cosmetic and pharmaceutical aqueous or aqueous-alcohol preparations.
BACKGROUND: One in 4 children with cerebral palsy (CP) will undergo orthopaedic surgery during their childhood. Despite its ubiquity, postoperative pain control has been poorly studied in this patient population. Moreover, poor pain management has been associated with adverse surgical outcomes. Multimodal analgesic injections have been well studied in the adult population, demonstrating safety and efficacy in reducing postoperative pain and narcotic consumption, but this modality has not been studied in pediatric patients undergoing similarly complex procedures. The objective of this study was to evaluate the efficacy of a multimodal surgical site injection for postoperative pain control following operative management of hip dysplasia in patients with CP.
METHODS: After obtaining IRB approval, a multicenter, randomized double-blind placebo control trial was completed. Patients below 18 years old with a diagnosis of CP who were scheduled for varus derotation osteotomy (VDRO) of the proximal femur were randomized to receive a surgical-site injection with either a combination of ropivacaine (3 mg/kg), epinephrine (0.5 mg), and ketorolac (0.5 mg/kg) (experimental group) or normal saline (control). All included patients had identical postoperative care, including immobilization, physical therapy, and standardized, multimodal postoperative pain control. Pain scores and narcotic consumption were recorded at regular intervals and compared between groups utilizing two-tailed t test or a nonparametric Mann-Whitney test for quantitative variables and a Fischer exact test for categorical variables.
RESULTS: Thirty-four patients were included, evenly divided between study arms. There were no significant differences in demographic variables, gross motor function classification system (GMFCS), comorbidities, preoperative radiographic parameters, or concomitant surgeries between groups. Patients in the experimental group required significantly lower narcotic medications at all postoperative time points from PACU until hospital discharge compared with controls (0.41 ± 0.42 vs. 1.87 ± 2.05 total morphine mEQ/kg, P =0.01). Similarly, patients in the experimental group were found to have significantly lower pain scores throughout their hospital stays compared with controls (1.0 ± 0.6 vs. 2.4 ± 1.1 mean pain score, P <0.001). There were no significant differences in operative time, OR time, blood transfusion requirements or hospital length of stay between groups. There were no adverse medication reactions or injection site complications in either group.
CONCLUSIONS: In patients with CP undergoing hip reconstruction, surgical-site injection with a multimodal analgesic combination improves pain control and reduces narcotic consumption in the early postoperative period with no observed adverse effects.
SIGNIFICANCE: Local multimodal analgesic injections should be adopted as part of standard multimodal pain control in this patient population for all osseous surgeries.
LEVEL OF EVIDENCE: Level I-therapeutic.
All subjects will receive treatment as is a single arm study. Two weeks of combined hypofractionated radiotherapy with concurrent temozolomide followed by up to 6 cycles of adjuvant temozolomide treatment.
INTRODUCTION: Chronic Obstructive Pulmonary Disease (COPD) is usually associated with sedentary behavior (SB). Literature reports a harmful impact of SB on the physical, mental, and social health of individuals with COPD. However, Pulmonary Rehabilitation (PR) programs seem to have no clear effect on changing SB. Therefore, our study aimed to identify the strategies used in the literature to reduce SB among individuals with COPD.
METHOD: A scoping review was conducted to summarize the current literature regarding the proposed strategies to reduce SB in individuals with COPD. Searches were conducted in PUBMED; SCOPUS and COCHRANE LIBRARY for studies published from 2010 to march 2024.
RESULTS: Twenty four articles were retained for our review. Most of the identified strategies in the literature (21/24 articles) are based on behavioral approaches, with various forms: promoting self-efficacy, self-management and self-regulation of one's own behavior (12 articles), goal setting (10 articles), constant feedback (11 articles), therapeutic education (8 articles), motivational strategies (6 articles), re-engagement in meaningful activities (4 articles), promoting light intensity physical activity (LPA) (6 articles) and social support (6 articles). In association with the behavioral strategies, wearable connected technologies have been used in 4 articles, alone or combined with physical exercise programs included or not in a PR program. The home is associated with 83 % of interventions as a place for initial and continuous implementation of behavioral strategies.
CONCLUSION: It would seem appropriate to focus on combined strategies to reduce SB in individuals with COPD (improvement of physical abilities and behavioral strategies). Further research is needed to only target the reduction of SB and to evaluate the effects of various interventions.
The Cerebral Vascular Accident (CVA) is a neurological deficit, which may be transitory or definite, leading to motor, psychological and social alterations. It's the third cause of death in the industrialized world, of which 90% of the survivors have some residual deficit and 30% become disabled. The objective of this study was to investigate the effects of the Swiss ball on patients with hemiplegia due to CVA. An intervening and controlled study was conducted on 12 patients of both genders and over 50 years old with chronic hemiplegia, all undergoing treatment at the Beneficent Rehabilitation Association of Ceará. The patients in the experimental group (EG) underwent treatment with the Swiss ball added to conventional physical therapy and the control group (CG) went through conventional physiotherapy sessions. The treatment was done twice a week, consisting of 14 sessions altogether. The data were collected in an evaluation form at the beginning and at the end of the treatment. Most patients were found to be males; they had typical walking ability, tonus, and posture of chronic hemiplegia patients. The patients in the experimental group showed significantly greater muscular strength on the lower limbs than the control group (p \< 0,05, Student t test), however, the same did not happen in the case of the other parameters, such as strength on the upper limbs, coordination, and balance. We can conclude that the treatment with the Swiss ball can promote increased strength, which will allow for a more efficient recovery in the studied population.
MR-130A-01 is a progestin-only TDS containing NGMN as its progestin. NGMN is currently available in combination with EE in CHC TDSs Xulane® (US) and Evra® (EU), at doses of 150 mcg/day (Xulane® USPI 2022) and 203 mcg/day (Evra®SmPC 2022) respectively. In the currently planned dose-finding clinical trial the ovulation inhibition and the impact on further physiological functions and hormones of the three dose strengths of MR-130A-01 will be investigated in healthy pre-menopausal obese and non-obese women with ovulatory menstrual cycles. Eligible subjects will be randomized according to their body mass index (BMI) into one of 7 treatment arms with different doses and regimens of IMP administration. The IMPs which are transdermal patches, will be applied to the skin (upper outer arm, abdomen, buttock or back) and will be changed weekly. Depending on the treatment arm, either 4 or 3 patches of an allocated patch strength will be applied per cycle (28/0-day regimen and 21/7-day regimen). Patch adhesion will be assessed by the subjects daily and the results (adhesion scores) will be recorded in a diary. Throughout the clinical trial, ovarian activity will be monitored by TVUS, and blood samples will be collected for determination of progesterone (P), estradiol (E2), LH and FSH concentrations. The inhibition of ovulation will be assessed by Hoogland and Skouby Score (HSS). In addition, bleeding pattern will be assessed based on the subject's records of bleeding and its intensity in a diary.
An approach for triggering an alert notification associated with an electronic prescription. The approach includes receiving an electronic prescription associated with a patient. The electronic prescription specifies a biometric parameter and a prescribed range for the biometric parameter. The approach also includes receiving a biometric value for the biometric parameter collected by a monitoring device based on the electronic prescription. The monitoring device is associated with the patient. The approach also includes triggering an alert notification based on a comparison of the biometric value against the prescribed range.
Intramuscular injections of nafcillin sodium, 1 gram produced peak serum levels in 0.5 to 1 hour of 7.61 mcg/mL. The degree of protein binding reported has been 89.9 +/-1.5%. With normal doses nafcillin is found in therapeutic concentrations in the pleural, bile, and amniotic fluids. Insignificant concentrations are found in the cerebrospinal fluid and aqueous humor. Blood concentrations may be tripled by the concurrent use of probenecid. Clinical studies with nafcillin sodium in infants under three days of age and prematures have revealed higher blood levels and slower rates of urinary excretion than in older children and adults. A high concentration of nafcillin sodium is excreted via the bile. About 30% of an intramuscular dose is excreted in the urine.